TriSalus Life Sciences is back in focus as analysts reset their fair value estimate from US$10 to US$8.25, reflecting a meaningful shift in how current upside is being framed. These changes follow recent Q3 results and a guidance reset, with research updates balancing concern around execution with interest in the TriNav platform and future procedure growth. As you read on, you will see how to track these evolving views and what to watch next in the TriSalus Life Sciences story. Stay updated...
WESTMINSTER, Colo., October 29, 2026--TriSalus Life Sciences® Inc. (Nasdaq: TLSI) ("TriSalus" or the "Company"), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, today announced that Mary Szela, Chief Executive Officer and President, and David Patience, Chief Financial Officer, will participate in Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services Forum. Management will participat
TriSalus Life Sciences (NASDAQ:TLSI) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide real-time
TriSalus Life Sciences secured FDA clearance for its TriNav Advance device, but shares face critical resistance levels amid a recent slide.
U.S. stocks fell as Nasdaq dropped 100+ points, while TriSalus surged 5.8% on FDA clearance; Securitize, Lakefront and others also gained.
TriSalus Life Sciences (NASDAQ:TLSI) shares rose 15. 6% in pre-market trading after the company announced that the U.
WESTMINSTER, Colo., September 22, 2026--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard-of-care therapies and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for TriNav® Advance, the newest addition to its Pressure-Enabled Drug Delivery™ (PEDD) portfolio.
WESTMINSTER, Colo., August 31, 2026--TriSalus Life Sciences to Participate in the H.C. Wainwright & Company 28th Annual Global Investment Conference
This is the newest page. Registered accounts read further back.